Trial Profile
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Apr 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary fibrosis; Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms INCREASE
- Sponsors United Therapeutics Corporation
- 20 Apr 2023 Results (n=242) of open-label extension study assessing long term effects of inhaled treprostinil in PH-ILD published in the European Respiratory Journal
- 14 Sep 2022 Results of post-hoc analysis assessing functional ability and clinical worsening in patients with PH-ILD published in the Chest
- 24 Aug 2022 According to a United Therapeutics Corporation media release, data on event-free survival in the open-label portion from the study will be presented at the European Respiratory Society (ERS) International Congress 2022.